Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UCL70805F in CD70-positive Advanced Renal Clear Cell Carcinoma
NCT07500805Phase 1Not yet recruiting
- Sponsor
- UTC Therapeutics
- Start
- May 2026
- Primary completion
- May 2028
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of UCL70805F in clear cell renal cell carcinoma (ccRCC), sponsored by UTC Therapeutics. Primary endpoints: Adverse Events at 2 years, Serious Adverse Events at 2 years and 1 more. Planned start May 2026; status: not yet recruiting.
02
Drugs
UCL70805F
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT07500805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07500805.